Fig 1: PDK1 Levels decrease with the treatment of nanoparticles loaded with PHT-427 on tumor of HNSCC. (A) The pPDK1 levels were measured by a colorimetric assay in protein extracts of tumor post-treatments. Experimental groups: control group (CTR) treated with 0.9% saline solution; unloaded nanoparticles group (NP-Ø) with a concentration of 1 mg/mL; PHT-427 inhibitor-free at concentrations of 0.5 and 1 mg/mL group (PHT-0.5 and PHT-1, respectively) and loaded nanoparticles with the PHT-427 inhibitor at the concentrations of 0.5 and 1 mg/mL groups (NP-0.5 and NP-1, respectively) for 21 d. The values represent the mean ± SD nm. *p < .05 versus CTR and NP-Ø groups (n = 32). (B) Representative fluorescence images of the immunostaining of PDK1 (green fluorescence) in tumor tissue. DAPI labels nuclei with blue fluorescence. Scale bar: 100 mm. The were taken at random in a blinded fashion. (C) The bar graphs show the immunofluorescence intensity changes for PDK1 by image J. The bar diagrams represent the mean ± SD of arbitrary units (AU). (n = 32).
Fig 2: Gene expression of the PI3K pathway. Gene expression of AKT1, AKT2, PDK1, PI3KCA, and PTEN in tumors of mice treated with 0.9% saline solution CTR group; unloaded nanoparticles group (NP-Ø) with a concentration of 1 mg/mL; PHT-427 inhibitor-free at concentrations of 0.5 and 1 mg/mL group (PHT-0.5 and PHT-1, respectively) and loaded nanoparticles with the PHT-427 inhibitor at the concentrations of 0.5 and 1 mg/mL groups (NP-0.5 and NP-1, respectively) for 21 days. The diagrams include the mean ± SD fold change (log10) (n = 32). Reference genes: GUSB and RPLP0.
Supplier Page from Abcam for Phospho-PDK1 (S241) and Total PDK1 ELISA Kit